|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007634,
umls-concept:C0012655,
umls-concept:C0022688,
umls-concept:C0024284,
umls-concept:C0024348,
umls-concept:C0024861,
umls-concept:C0033684,
umls-concept:C0431085,
umls-concept:C1334545,
umls-concept:C1524063,
umls-concept:C1704222,
umls-concept:C2349975
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
1989-2-23
|
|
pubmed:abstractText |
The role of major histocompatibility gene products (i.e., HLA molecules) in rendering tumor cells resistant to natural killer (NK) cell-mediated lysis was investigated by using mouse monoclonal antibodies to bind and mask HLA or non-HLA gene products on the cell membrane of human allogeneic tumor targets. Enhanced lysis of resistant lymphoid and certain other solid tumor cell lines was observed only when monoclonals used reacted to class I and II HLA molecules but not non-HLA molecules on tumor targets. Enhanced lysis was not due to antibody dependent cellular cytotoxicity or due to an effect of antibody on NK effectors. Of importance, normal autologous and allogeneic human lymphocytes could not be lysed by NK cells despite blast transformation with mitogens or masking of HLA membrane determinants on blasts with monoclonal antibodies. Enhanced lysis, in the presence of antibody to HLA antigens, was not due to increased NK cell binding to tumor targets, but a consequence of enhanced postbinding lysis. Studies using granules obtained from NK cells indicated that masking of HLA antigens did not enhance the susceptibility of tumor targets to cytolysins. Such observations would suggest that HLA antigens on tumor targets inhibit the triggering of effector cells (and release of cytolysins) after recognition and binding of NK cells to target cells.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/2463268-2426704,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2463268-2437198,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2463268-2944117,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2463268-300395,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2463268-3126240,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2463268-315432,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2463268-319572,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2463268-325136,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2463268-3351305,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2463268-3489775,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2463268-3518752,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2463268-3724757,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2463268-3819393,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2463268-3873616,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2463268-3877776,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2463268-3878030,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2463268-3921497,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2463268-392522,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2463268-3951539,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2463268-3965573,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2463268-3975631,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2463268-4617353,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2463268-53240,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2463268-6162228,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2463268-6172474,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2463268-6200433,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2463268-6358356,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2463268-6395653,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2463268-6402547,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2463268-6736872,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2463268-6966655,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2463268-7024219,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2463268-761939,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2463268-94425
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0021-9738
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
83
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
278-87
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:2463268-Animals,
pubmed-meshheading:2463268-Antibodies, Monoclonal,
pubmed-meshheading:2463268-Antibody-Dependent Cell Cytotoxicity,
pubmed-meshheading:2463268-Cell Line,
pubmed-meshheading:2463268-Epitopes,
pubmed-meshheading:2463268-Genes, MHC Class II,
pubmed-meshheading:2463268-Histocompatibility Antigens,
pubmed-meshheading:2463268-Histocompatibility Antigens Class I,
pubmed-meshheading:2463268-Killer Cells, Natural,
pubmed-meshheading:2463268-Mice
|
|
pubmed:year |
1989
|
|
pubmed:articleTitle |
Use of anti-HLA antibodies to mask major histocompatibility complex gene products on tumor cells can enhance susceptibility of these cells to lysis by natural killer cells.
|
|
pubmed:affiliation |
Department of Internal Medicine, University of Virginia School of Medicine, Charlottesville 22908.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
